Sleep Disorders and Medical Conditions in Women by Phillips, Barbara A. et al.
JOURNAL OF WOMEN’S HEALTH
Volume 17, Number 7, 2008
© Mary Ann Liebert, Inc.
DOI: 10.1089/jwh.2007.0561
Sleep Disorders and Medical
Conditions in Women
Barbara A. Phillips, M.D., MSPH,1 Nancy A. Collop, M.D.,2 Christopher Drake, Ph.D.,3
Flavia Consens, M.D.,4 Alexandros N. Vgontzas, M.D., Sc.D.,5 and Terri E. Weaver, Ph.D., R.N.6
Abstract
Sleep disorders affect women differently than they affect men and may have different manifestations and preva-
lences. With regard to obstructive sleep apnea (OSA), variations in symptoms may cause misdiagnoses and delay
of appropriate treatment. The prevalence of OSA appears to increase markedly after the time of menopause. Al-
though OSA as defined by the numbers of apneas/hypopneas may be less severe in women, its consequences are
similar and perhaps worse. Therapeutic issues related to gender should be factored into the management of OSA.
The prevalence of insomnia is significantly greater in women than in men throughout most of the life span. The
ratio of insomnia in women to men is approximately 1.4:1.0, but the difference is minimal before puberty and in-
creases steadily with age. Although much of the higher prevalence of insomnia in women may be attributable to
the hormonal or psychological changes associated with major life transitions, some of the gender differences may
result from the higher prevalence of depression and pain in women. Insomnia’s negative impact on quality of life
is important to address in women, given the high relative prevalence of insomnia as well as the comorbid disor-
ders in this population. Gender differences in etiology and symptom manifestation in narcolepsy remain under-
studied in humans. There is little available scientific information to evaluate the clinical significance and specific
consequences of the diagnosis of narcolepsy in women. Restless legs syndrome (RLS) is characterized by an urge
to move the legs or other limbs during periods of rest or inactivity and may affect as much as 10% of the popula-
tion. This condition is more likely to afflict women than men, and its risk is increased by pregnancy. Although RLS
is associated with impaired quality of life, highly effective treatment is available.
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Introduction
THE EFFECTS OF SLEEP LOSS and sleep disturbance on centralnervous system (CNS) function and human behavior
have long been recognized. However, the association of sleep
loss and sleep disorders with physical health has received
clinical and research attention only recently. Further, inves-
tigations of sleep disturbances and disorders specifically in
women are scant. The aim of this review is to update the
clinician about sleep apnea, sleep and metabolic disorders,
insomnia, narcolepsy, and restless legs syndrome (RLS) in
women. This paper is a summary of reviews on sleep disor-
ders and medical conditions presented at the Women and
Sleep Workshop, convened by the National Sleep Founda-
tion and the Atlanta School of Sleep Medicine in Washing-
ton DC, March 5–6, 2007.
Sleep Disordered Breathing and Metabolic Disorders
Epidemiology
Obstructive sleep apnea (OSA) has been historically de-
scribed as a disease of men, with early clinical research show-
ing the estimated male/female ratio for disease prevalence
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to be 10:1–60:1.1 However, these prevalence estimates were
based on clinical studies that often had a referral bias. Newer
studies suggest the male/female prevalence ratios are much
lower, probably in the range of 3:1–2:1. In addition, women
with OSA may have different clinical presentations, thera-
peutic considerations, and prognoses than do their male
counterparts.
Diagnosis
In examining the diagnostic testing for OSA, there are sev-
eral characteristics that differ between the genders. Women
with OSA are more likely to have partial obstructions (hy-
popneas) than complete obstructions (apneas), and the respi-
ratory disturbances have shorter mean and maximum dura-
tions.2 In addition, women are more likely to have the upper
airway resistance syndrome (UARS), a milder form of OSA;
less likely to have positional OSA; and generally have the same
severity of OSA but at higher body mass indices (BMI) com-
pared with men.2–6 Perhaps the most striking difference be-
tween men and women is that women are much more likely
to have rapid eye movement (REM)-related OSA.6,7
Presentation
Several factors could contribute to the discrepancy be-
tween the gender ratio of OSA in the general population and
the proportion of clinically diagnosed OSA. These include
gender-related differences in frequency or atypical symptom
reports,8–11 differences between self-report and spouse re-
port,12 and failure of physicians to recognize sleep apnea in
women. The last is of particular importance, as there is evi-
dence of higher healthcare use in women with OSA prior to
receiving the diagnosis.13 Women with sleep apnea are more
likely than men to have insomnia complaints, less likely to
have been witnessed to have apnea by their bed partner dur-
ing sleep, and frequently have concomitant depression, hy-
pothyroidism, restless legs, nightmares, palpitations, and
hallucinations.8–10 Further, tools that are commonly used to
assess sleep apnea symptoms perform differently when ap-
plied to men and women. For example, the Epworth Sleepi-
ness Scale14 is more likely to identify men with sleepiness
than women.10,11 Because of these differences in symptoms
and presentation, it is possible that women are underreferred
and underdiagnosed because they do not have the classic
symptoms of excessive sleepiness and snoring.
Pathophysiology of gender differences
The differences in anatomy and physiology of the upper
airway and control of breathing may play a role in the gen-
der-related differences of OSA. Neck soft tissue volume is
greater in men than in women,15,16 and men have larger soft
palates and upper tongue volume, with a longer phar-
ynx.15,17 Furthermore, although men have a greater upper
airway diameter during wakefulness, they have more nar-
rowing of the oropharyngeal space in the supine position
compared with women.16–19 The contribution of obesity as a
known risk factor for OSA in and of itself does not differ be-
tween genders except that women with OSA are likely to be
more obese but men exhibit greater upper body obesity, as
measured by smaller hip circumferences and greater sub-
scapular skinfold thickness.20 Men also have different re-
sponses of ventilatory drive to oxygen and carbon dioxide,
which appears to predispose them to greater ventilatory in-
stability during sleep.
Multiple hormonal influences affect the presentation and
consequences of sleep-disordered breathing in women. Es-
trogen and progesterone have been implicated in the gender
differences in OSA. In one study, women with OSA had sig-
nificantly lower levels of 17-hydroxyprogesterone, proges-
terone, and estradiol than those without OSA.21 Testosterone
seems to precipitate or worsen OSA. Exogenous adminis-
tration of testosterone hormone for treatment of hypogo-
nadism in men has been associated with an increase in the
apnea-hypopnea index (AHI), and exogenous testosterone
administration to 1 woman was reported to precipitate clin-
ically significant OSA.22,23
Women with polycystic ovarian syndrome (PCOS), which
is characterized by ovarian failure, obesity, and androgen ex-
cess, appear to be at higher risk for OSA than are healthy
women controls.24 The relationship between sleep apnea and
PCOS is a complicated one. Many studies, primarily in men,
have shown that sleep apnea is associated with elevation of
proinflammatory cytokines, insulin resistance, and visceral
adipocity.25–31 These associations have not been studied in
women with sleep apnea. However, the link between sleep
apnea and insulin resistance led investigators to study the
presence of sleep apnea in disorders in which insulin resis-
tance is the primary pathogenetic mechanism. Several recent
studies have established a strong link among PCOS, sleep
apnea, and excessive daytime sleepines.24,31,32 Further,
proinflammatory cyto-kines are elevated in women with
PCOS, independent of obesity and sleep apnea, and are
strongly connected with insulin resistance, providing further
support for the hypothesized role of cytokines in sleep ap-
nea, sleepiness, and cardiovascular morbidity.33,34 Interest-
ingly, the use of cytokine neutralizing antibodies and regu-
lar exercise, possibly by improving insulin sensitivity, are
beneficial in patients with sleep apnea.35,36
Menopause is associated with cessation of ovarian endocrine
function, causing a reduction in endogenous estrogen and pro-
gesterone levels. The prevalence and clinical severity of OSA
in women increase dramatically after menopause, with post-
menopausal women having nearly double the rate of OSA as
that observed in premenopausal women, even when account-
ing for neck circumference and BMI.37,38 The reasons for this
appear to be multifactorial, perhaps related to changes in body
habitus and overall fat distribution and differences in airway
function related to hormonal changes.39,40
A cardinal symptom of OSA in men is sleepiness, and this
symptom appears to be much less specific in women than in
men.8–11 Excessive daytime sleepiness (EDS) affects 10%–
20% of the general population, and major risk factors include
depression and obesity, conditions that are more prevalent
in women.41,42 In a study of 5508 Swedish women, depres-
sion and anxiety were the most important predictors of
EDS.43 Also, physical inactivity is independently associated
with EDS and fatigue in the general population,43,44 as well
as in patients with sleep apnea.45
Treatment
Continuous positive airway pressure (CPAP). Treatment
of OSA should not be different for women than for men, but
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there are some nuances of treatment between genders that
are worth mentioning. Nasal CPAP is the therapy of choice
for OSA. The effectiveness of CPAP therapy depends heav-
ily on consistent use. Only about half of those with sleep ap-
nea use their CPAP nightly, and the decision to adhere to
CPAP therapy is made early in the treatment period, typi-
cally during the first week.46 Thus, adherence to CPAP ther-
apy is a significant challenge for clinicians.
The optimal nightly duration of CPAP use to restore nor-
mal functioning depends on the outcome of interest. For ex-
ample, the greatest proportion of individuals with subjective
sleepiness will have normal values for subjective sleepiness
with average use of 4 hours per night, but improvement in
objective sleepiness to normal levels requires 6 hours.47 A
limited body of research examining gender differences in
CPAP treatment adherence provides some support for gen-
der-based differences in adherence, although findings are
not consistent. One study of older sleep apnea patients found
that female gender was predictive of better CPAP use,48
whereas another showed that female CPAP use was on av-
erage significantly less than that of male participants.49
A study on the determinants of long-term CPAP use found
that women were more likely to initially refuse CPAP treat-
ment and to later abandon its use.50 In sum, results of stud-
ies to determine the role of gender in predicting adherence
to CPAP are conflicting, with men more likely to be adher-
ent in some and women in others.48–51 In addition to the in-
consistent data on CPAP adherence, gender differences in
the response to CPAP treatment are virtually unknown.
In the general population, improvements in functional sta-
tus as well as such symptoms as daytime sleepiness and
mood disturbances have been documented.52,53 Most of the
research has been conducted in predominantly male samples
with severe OSA, however, and has failed to examine gen-
der-specific results. Consequently, it remains unclear
whether women’s responses to treatment are similar to those
of men. Small sample sizes and high male/female ratio seen
in the clinical trials, especially in those only including pa-
tients with severe OSA, might prohibit meaningful gender-
based comparisons in CPAP treatment response.
A final challenge with regard to CPAP treatment for
women is their increased likelihood of milder disease; pre-
vious criteria for Medicare reimbursement for CPAP treat-
ment were viewed as an unintended bias facing women with
OSA.54 For example, an AHI of 30 was required for CPAP
Medicare reimbursement. Most female patients might have
a milder disease, with an AHI of 5–30, which was reflected
by the observed increase in male/female ratio from 2:1 for
mild OSA to 7:1 for severe OSA in a large retrospective
study.6 Therefore, a large number of women with milder
OSA would have been denied treatment. Fortunately, the
new Medicare guidelines for reimbursement published in
2002 are more liberal and, therefore, might lessen this unin-
tended gender bias.55
Mandibular advancement devices. The use of dental/oral
appliances (OA), a second-line treatment for OSA, has also
been examined regarding success between genders. In one
large prospective study, women with OSA were more likely
to have treatment success with OA than men, particularly
those with milder forms of OSA.56 Men with OSA treated
with OA were more likely to have treatment success when
they had predominantly supine-dependent OSA and were
more likely to develop treatment failure with even small
changes in their BMI.57,58
Upper airway surgery. There are sparse data about poten-
tial gender differences in the outcome of upper airway sur-
gery for the treatment of OSA, but one report suggests no
gender-related differences in the use or side effects of
mandibular advancement devices.59
Weight loss. Weight loss is an important treatment strat-
egy for OSA; however, in one large community-based study,
weight loss was found to be a more effective treatment strat-
egy in men than in women.60
Hormone replacement therapy (HRT). Finally, because of
the sharp upswing in OSA prevalence at menopause, it is
reasonable to consider the effects of HRT on sleep-disordered
breathing (SDB). Three large, well-done cohort studies dem-
onstrated a reduced risk for sleep apnea in postmenopausal
women who are taking HRT.37,61,62 In the Sleep Heart Health
Study,61 women who were on HRT were less likely to have
sleep apnea than those who were not, but overall lifestyle
and healthcare are significant confounders in drawing con-
clusions about the efficacy of HRT for OSA. There are a few
small interventional studies of HRT in SDB, but data are con-
flicting and limited.63 This discrepancy between observa-
tional and treatment studies will need to be clarified before
firm recommendations can be made. Estrogen is an option
to consider, but it would need to be discussed carefully with
the patient because of recently recognized complications of
HRT. Thus, management of sleep apnea in women is chal-
lenging. In one study, however, women with OSA had in-
creased cardiovascular mortality compared with men; thus,
although OSA is more common in men than women, the




Population-based studies have found that 30% or more of
the general population complain of sleep disturbances. How-
ever, it is important to distinguish the disorder of insomnia
from the experience of short-term sleep disturbance. Sleep
disturbance is often a transient response to identifiable stim-
uli and may not be associated with daytime consequences.
In contrast, insomnia is a disorder characterized by chronic
and frequently reported difficulty with sleep induction or
maintenance or nonrestorative sleep, lasting a minimum of
1 month and associated with significant impairment in so-
cial, occupational, or other areas of functioning.65 Insomnia
is also associated with significant morbidity, including re-
duced quality of life, falls in the elderly, and increased ab-
senteeism, and is a risk factor for the development of major
depression.66–68 Importantly, women of all ages have a
higher prevalence of both sleep disturbance and insomnia
than do men.69
The prevalence of DSM-IV-based insomnia (as opposed to
sleep disturbance) in the general population is estimated to
be between 9% and 15%. These epidemiological studies are
based on data collected over virtually the entire life span.69
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One consistent finding among this large body of literature is
the higher rate of insomnia found in women. A recent meta-
analysis combining data from more than 29 studies encom-
passing 1,265,015 individuals demonstrated that women are
at 41% greater risk for developing insomnia than are men.70
Furthermore, the greater risk of insomnia in women in-
creases with age. In elderly populations ( 65), the risk al-
most doubles, to a 73% greater risk for insomnia in older
women than in older men. This higher prevalence of in-
somnia in women probably does not emerge until puberty,
suggesting a possible contribution of hormonal changes.71
This study also found that increased rates of insomnia are
associated with maturation during puberty in girls only.
Comorbid insomnia
The recent National Institutes of Health (NIH) State of the
Science Conference on insomnia highlighted the fact that in-
somnia is most often comorbid with other conditions.72 In a
recent National Sleep Foundation (NSF) poll, the presence of
greater numbers of comorbid conditions was associated with
significantly reduced sleep quality.73 However, it is often dif-
ficult to determine the nature of this association between in-
somnia and the comorbidity or the direction of causality. Is-
sues related to the assessment and treatment of insomnia in
women are particularly important in this regard, as many of
the common co-morbidities with insomnia also have a higher
prevalence rate in women.74
The most common comorbid conditions with insomnia are
psychiatric diseases.75 Among psychiatric conditions, major
depression and dysthymia, disorders with a much higher
prevalence in women, are the disorders most closely associ-
ated with insomnia.76 In fact, a primary symptom of de-
pression is sleep disturbance. Even after successful treatment
of depression, however, several refractory symptoms may
remain. Interestingly, sleep disturbance is the single most
common refractory symptom in successfully treated de-
pressed patients,77 suggesting the possibility that in many
cases, insomnia may be an independent comorbid condition
rather than merely a secondary symptom of the depression.
Indeed, there is evidence that insomnia is associated with an
overall increase of ACTH and cortisol secretion, which sug-
gests that insomnia may be a disorder of CNS hyper-
arousal.78 In fact, recent studies have shown that specific
treatment of insomnia in depressed patients not only im-
proves the sleep disturbance but also reduces depressive
symptomatology.79 Thus, it is important to consider insom-
nia and its treatment as an important and independent as-
pect of the overall care of women with depression.
Other common comorbidities with insomnia that also have
a higher prevalence in women are chronic pain disorders. In
fact, numerous studies have shown a close link between pain
and insomnia, including the 2003 NSF Sleep in America poll,
which showed that individuals who report bodily pain are 1.89
(95% C.I. 1.28-2.78), 2.68 (95% C.I. 2.06-3.49), 1.88 (95% C.I. 1.32-
2.66), and 2.11 (95% C.I. 1.54-2.90) times more likely to report
“difficulty falling asleep,” “frequent awakenings,” “waking
too early,” or “waking unrefreshed,” respectively.73 Not only
does pain impact sleep, but sleep loss can have a significant
impact on pain. One recent laboratory-controlled study
showed that reductions in total sleep time significantly increase
pain sensitivity, even in healthy, disease-free individuals.80
Treatment
At present, there are very few data regarding potential dif-
ferential treatment effects of insomnia in women. Nonethe-
less, there is a vast treatment literature demonstrating the 
effectiveness of both behavioral and pharmacological treat-
ment approaches to insomnia in men and women.81 Research
has shown that the FDA-approved GABAA receptor ago-
nists including older benzodiazepines and newer medica-
tions, such as eszopiclone, zaleplon, zolpidem, zolpidem-CR,
and the melatonin 1 and 2 receptor agonist ramelteon, are
effective at reducing sleep onset latency in samples of pri-
mary insomniacs, including women.82 Beneficial effects on
reducing wake after sleep onset are also observed with the
medications that have intermediate half-lives. However, the
risk for residual daytime impairment increases with longer-
acting compounds.
Given the high rate of comorbidity with insomnia, it is im-
portant to consider treatment effects in insomnia coexisting
with specific medical and psychiatric conditions. Treatment
studies of comorbidities with a higher prevalence in women,
such as depression and pain, are particularly germane in the
present context. Despite the lack of data on long-term effi-
cacy in insomnia, sedating antidepressants continue to be
widely used in the context of treating sleep disturbance in
depression. Several controlled studies have shown im-
provement in the sleep of depressed patients with coexist-
ing insomnia when treated with newer as well as older 
hypnotic medications in conjunction with standard antide-
pressant treatment.83 In one study, depression outcome was
improved with cotherapy of a hypnotic and an antidepres-
sant in comparison to antidepressant therapy alone.79 In an-
other study of comorbid insomnia and rheumatoid arthritis,
patients reported improvement in sleep and morning stiff-
ness after treatment with the short-acting hypnotic triazo-
lam.84 Eszopiclone has been shown to improve sleep and
menopause-related symptoms in perimenopausal and early
postmenopausal women with insomnia.85 Future studies are
needed to confirm these studies that demonstrate the bene-
fit of hypnotic medications on both sleep and nonsleep out-
comes.
Controlled studies have demonstrated improved sleep
with cognitive behavioral treatments of insomnia in both
men and women. This treatment strategy typically includes
sleep hygiene instructions, stimulus control, sleep restriction
therapy, and relaxation techniques used in combination.81
Similar to pharmacological treatment, cognitive behavioral
treatment of insomnia has been shown to improve sleep in
insomnia comorbid with a number of medical and psychi-
atric conditions.72,81 The benefits of this type of treatment
have been shown to produce sleep improvements over long-
term ( 6 months) follow-up. Behavioral treatments of in-
somnia associated with pain have demonstrated significant
improvements in sleep and may even impact the level of pain
as well.86,87
Narcolepsy
Narcolepsy is a life-long neurological disorder character-
ized by EDS and abnormal REM sleep manifestations, in-
cluding cataplexy, sleep paralysis, hypnagogic hallucina-
tions, and sleep-onset REM periods. Nocturnal sleep is
usually disturbed. The International Classification of Sleep
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Disorders (ICSD-2)88 differentiates three types of narcolepsy:
with cataplexy, without cataplexy, and secondary narcolepsy
(when the direct cause of narcolepsy is a coexisting medical
disorder). This review focuses primarily on narcolepsy with
cataplexy.
Cataplexy is the brief, sudden transient loss of muscle tone
triggered by strong emotions. Consciousness is preserved.
Whether there are gender differences in cataplexy remains
controversial: it has been reported there are no gender dif-
ferences in symptom severity89 but that women develop cat-
aplexy at a younger age.90
Epidemiology
Narcolepsy with cataplexy affects 0.02%–0.18% of the
United States and Western European population.79 Preva-
lence in the general population increases to 25–56 per 100,000
when cataplexy is not a required symptom for diagnosis, and
male predominance has been reported using this definition
(relative risk 1.6:1). Silber et al.91 report a greater relative risk
of narcolepsy with cataplexy in men compared with women
(1.2:1).
Pathogenesis
The exact etiology of narcolepsy is unknown. The associ-
ation with HLA DQB1*0602 is well established, suggesting
both a genetic component and a possible autoimmune etiol-
ogy for the disease. In an animal model of narcolepsy, fe-
male Doberman puppies have more severe cataplexy
episodes than do male puppies, which may suggest that the
pathophysiological process involved in the canine nar-
colepsy model may involve differential development in fe-
males and males.92 The loss of hypocretin/orexin is a con-
sistent finding in subjects with this disorder. These
neuropeptides are localized to a few neurons in the dorso-
lateral hypothalamus. These hypocretin/orexin neurons
project widely throughout the brain and appear to stabilize
vigilance states.
Daniels,93 in 1934, noted that half of his narcoleptic pa-
tients gained a considerable amount of weight when diag-
nosed with this disorder, a finding that was more frequent
in women. Mice lacking hypocretin/orexin peptide manifest
symptoms of narcolepsy with cataplexy. Female mice lack-
ing hypocretin/orexin are obese, but male mice are not; the
reason for this difference is not known, but leptin levels are
influenced by sex, hormones, and cytokines. Female rats
have higher levels of preprohypocretin mRNA in the hypo-
thalamus, and leptin affects its signaling. Elucidating the 
underlying mechanisms of gender differences in prepro-
hypocretin may also contribute to our understanding of obe-
sity.94
Tumor necrosis factor- (TNF-) is elevated in some sleep
disorders characterized by EDS, including narcolepsy.25
Himmerich et al.95 suggested that narcoleptic patients have
a functional alteration in the TNF- cytokine level, a differ-
ence mainly found in women. Okun et al.96 reported that
narcoleptic subjects have higher serum levels of TNF- and
interleukin-6 (IL-6). Although no gender differences in these
cytokines were reported, the possibility remains that cyto-
kines may be involved in the development of narcolepsy.
Gender differences may be an important consideration in the
treatment of narcolepsy, although clinical studies address-
ing pharmacogenetics are lacking. Dauvilliers et al.97 re-
ported that the optimal dose of modafinil for narcoleptic
women is approximately 100 mg lower than that for men,
probably because of the sexual dimorphism of the catechol-
O-methyltransferase (COMT) gene, which plays a crucial
role in the metabolism of dopamine.
Impact on quality of life
Narcolepsy clearly has a negative effect on the quality of
life, most profoundly affecting bodily pain, social function,
and general health. Whether or not there are gender differ-
ences in symptom onset or severity in narcoleptic subjects,
women express more social limitations as a result of this
sleep disorder than do men.98
Treatment
The importance of sleep hygiene must be emphasized. Be-
havioral measures to enhance alertness during critical times
of the day must be considered. Scheduled naps are often help-
ful. If medications are needed, these are directed toward
symptomatic improvement. For the treatment of EDS, wake-
promoting agents (such as modafinil) or stimulants (such as
methylphenidate or dextroamphetamines) improve alertness
in most narcoleptics. For treatment of cataplexy, serotonin 
reuptake inhibitors (SSRIs) and tricyclic antidepressants are
effective. Gamma-hydroxybutyrate (GHB) treats more severe
cataplexy and improves daytime sleepiness as well.
There are no controlled studies in humans regarding the
safety of these medications during pregnancy. As the po-
tential for teratogenicity is unknown, each case must be ad-
dressed individually to carefully evaluate the benefits of the
treatment over potential risk to the fetus.
Restless Legs Syndrome
According to the International Classification of Sleep Dis-
orders,99 the diagnosis of RLS in adults can be made when:
A. The patient reports an urge to move the legs, usually ac-
companied or caused by uncomfortable and unpleasant
sensations in the legs.
B. The urge to move or the unpleasant sensations begin or
worsen during periods of rest or inactivity, such as lying
or sitting.
C. The urge to move or the unpleasant sensations are par-
tially or totally relieved by movement, such as walking
or stretching, or at least as long as the activity continues.
D. The urge to move or the unpleasant sensations are worse
or only occur in the evening or night.
F. The condition is not better explained by another current
sleep disorder, medical or neurological disorder, mental
disorder, medication use, or substance use disorder.
Epidemiology
As many as 90% of people with RLS have periodic limb
movements (PLMs) during sleep.100 The rate of PLMs cor-
relates with subjective RLS severity,101 and PLMs that are as-
sociated with arousals are associated with disturbed sleep in
older women.101 It is important to note, however, that PLMs
are very common with many sleep disorders, including
SDB.102 Periodic leg movements are not more prevalent in
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insomnia or hypersomnia but are specifically associated with
sleep disorders involving dopaminergic impairment.103 They
also increase with aging104 and are frequently seen in pa-
tients who are taking antidepressants.105 Thus, whereas the
presence of PLMs supports the diagnosis of RLS, limb move-
ments are neither necessary nor sufficient to make the diag-
nosis.
The prevalence of RLS symptoms is about 10% in most
population-based surveys, and there are consistently higher
rates of RLS symptoms in women than in men.106–109 The
rate of RLS may be lower in Asian than in European popu-
lations,110 but the prevalence in African Americans is simi-
lar to that in Caucasians.111 Because the diagnosis of RLS is
based on symptom report, prevalence rates vary with dif-
ferent criteria for frequency and severity. For example, in the
Restless Legs Syndrome Prevalence and Impact (REST)
study, RLS symptoms were endorsed by 7.2% of the survey
population. However, symptoms occurring at least twice per
week were reported by only 5% of the subjects and were
moderately or severely distressing in only 2.7%.112
Pathophysiology
RLS may be classified as primary or secondary. Primary
or idiopathic RLS is more likely to develop at an earlier age,
may have no known associated or predisposing factors, and
appears to have a genetic basis. First-degree and second-de-
gree relatives of patients with idiopathic RLS have a signif-
icantly increased risk of developing RLS compared with rel-
atives of matched controls.112 RLS may also be secondary to
a variety of medical conditions that have iron deficiency in
common; these include iron-deficiency anemia, end-stage re-
nal disease, and pregnancy.113
Pregnancy is an important risk factor for RLS, both dur-
ing the pregnancy and in subsequent years.107,114,115 About
a quarter of pregnant women experience RLS symptoms, es-
pecially in the third trimester. Symptoms typically resolve
promptly with delivery. Lower hemoglobin, mean corpus-
cular volumes, and serum folate levels appear to be risk fac-
tors for RLS in pregnancy.114,115 In the years after pregnancy,
the risk of RLS is associated with bearing children in a dose-
dependent way. In one study, nulliparous women had the
same risk for RLS as did men up to age 64. However, for
women who had borne children, the risk of RLS increased
with the number of children. A woman with one child had
twice the risk of RLS as a nulliparous woman, and the risk
increased with additional children.107
Understanding of the pathophysiology of RLS is currently
an active area of research, and dysfunction of both iron and
dopamine have been implicated.116
Impact on quality of life
Quality of life in patients with RLS is reduced to a degree
equivalent to the reduction seen in patients with other chronic
diseases.108 Adults with symptoms of RLS may be at increased
risk for sleep apnea, insomnia, drowsy driving, being late to
work, missing work, and making errors at work.117 RLS is also
associated with anxiety and depression.118
Treatment
The treatment of RLS includes both behavioral and phar-
macological approaches. Exercise in moderation may be ben-
eficial.119 Folic acid has been reported to improve symptoms
in pregnant patients with RLS who are folate deficient.120
Iron replacement appears to reduce or eliminate symptoms
in patients who have serum ferritin levels 45 g/L.121
There are many anecdotal reports of relief with moderate ex-
ercise, massage, caffeine and alcohol avoidance, vitamins,
and hot baths. Patients may benefit from being empowered
to try these approaches.
Dopaminergic therapy is clearly first-line pharmacologi-
cal treatment and is very effective in improving or elimin-
ating symptoms.122 Two medications, ropinirole and
pramipexole are FDA approved for the treatment or RLS, but
they are not safe for use in pregnant or nursing women.
Conclusions
Women are more likely to have sleep complaints than are
men for several reasons, including hormonal changes through-
out the life span, the increased likelihood of an atypical pre-
sentation of OSA, a higher prevalence of depression, and 
increased likelihood of RLS. As most sleep disorders are treat-
able, increased awareness of the presentation and impact of
sleep disorders in women can improve health and quality of
life outcomes for these patients. Future investigation of the dif-
ferences between men and women in the impact and treatment
effects of sleep disorders is urgently needed.
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